Brian Patterson, MD
Family Medicine · Bellingham, WANPI 1982792131
Payments from drug & device makers
Across 359 payments — averaging $12.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$794
- Johnson & Johnson$566
- Novo Nordisk$492
- Pfizer$452
- Boehringer Ingelheim$368
- Amgen$364
- plus $1K from 20 others
What the payments were for
- Consulting fees$1503%
- Food & beverage$4,32996%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $794 |
| Johnson & Johnson | 36 | $566 |
| Novo Nordisk | 65 | $492 |
| Pfizer | 60 | $452 |
| Boehringer Ingelheim | 19 | $368 |
| Amgen(2 entities) | 23 | $364 |
| Lilly USA, LLC | 31 | $346 |
| Teva Pharmaceuticals USA, Inc. | 28 | $264 |
| E.r. Squibb & Sons, L.L.C. | 11 | $178 |
| Comsort, Inc | 1 | $150 |
| Supernus Pharmaceuticals, Inc. | 14 | $125 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| Astellas Pharma US Inc | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| GSK | 3 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $31 |
| Bioventus LLC | 1 | $30 |
| Merck | 3 | $28 |
| Abbott | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Philips North America LLC | 1 | $18 |
| Novartis | 1 | $15 |
| AbbVie | 1 | $12 |
| Boston Scientific | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GARDASIL$150
How this compares
$4,508 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 48 | $1,044 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 39 | $819 |
| Losartan Potassium | 28 | $706 |
| Fluconazole | 11 | $645 |
| Atorvastatin Calcium | 61 | $568 |
| Tamsulosin Hcl | 20 | $542 |
| Valsartan | 17 | $459 |
| Pioglitazone Hcl | 15 | $370 |
| Lisinopril | 38 | $361 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $359 |
| Omeprazole | 32 | $343 |
| Metoprolol Succinate | 21 | $333 |
| Duloxetine Hcl | 31 | $330 |
| Amlodipine Besylate | 34 | $320 |
| Olmesartan Medoxomil | 11 | $318 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Bellingham
- James MorenBellingham$106K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.